All In Biotech

Drug Trial Radar · NCT03514108

DANHEART (H-HeFT and Met-HeFT)

A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT)

Last checked: Nov 20, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,100

Actual

Start

Mar 1, 2018

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Henrik WiggersAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Danish Heart Foundation; Danish Council for Independent Research; The Danish Regions: Foundation for Medical Research; Novo Nordisk Foundation; The Aase og Ejnar Danielsen Foundation
First posted
May 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The present study is testing in a combined design to types of drugs in patients with chronic heart failure: 1) Hydralazine in combination with isosorbide dinitrate (BiDil) and 2) Metformin hydrochloride. The study is double blind, placebo controlled. 1. The first hypothesis is that hydralazine in combination with isosorbide dinitrate can reduce mortality and hospitalization with worsening heart failure in chronic heart failure patients with reduced LVEF. 2. The second hypothesis is that treatment with metformin in chronic heart failure patients with reduced LVEF and type 2 diabetes / diabetes risk / insulin resistance can reduce mortality and cardiovascular hospitalizations. Among secondary endpoints are reduction in new-onset diabetes in heart failure patients with insulin resistance and diabetes risk profile and patient safety.

Conditions

  • Heart Failure
  • Diabetes

Interventions

  • Hydralazine Isosorbide DinitrateDrug

    Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily

  • Placebo Oral TabletDrug

    2 tablets x 3 daily

  • Metformin HydrochlorideDrug

    Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)

  • Placebo Oral TabletDrug

    2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. H-HeFT combined primary endpointTime frame: Through study completion, an average of 4 years
  2. Met-HeFT combined primary endpointTime frame: Through study completion, an average of 4 years

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Sygehus Sønderjylland, Aabenraa

    Aabenraa, Denmark

  • Aalborg University Hospital

    Aalborg, Denmark

  • Aarhus University Hospital

    Aarhus, Denmark

  • Amager Hospital

    Copenhagen, Denmark

  • Bispebjerg Hospital

    Copenhagen, Denmark

  • Gentofte Hospital

    Copenhagen, Denmark

  • Glostrup Hospital

    Copenhagen, Denmark

  • Herlev Hospital

    Copenhagen, Denmark

  • Hvidovre Hospital

    Copenhagen, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Sydvestjysk Sygehus, Esbjerg

    Esbjerg, Denmark

  • Herning Hospital

    Herning, Denmark

  • Nordsjællands Hospital Hillerød

    Hillerød, Denmark

  • Regionshospital Nordjylland, Hjørring

    Hjørring, Denmark

  • Holbæk Hospital

    Holbæk, Denmark

  • Horsens Hospital

    Horsens, Denmark

  • Kolding Hospital

    Kolding, Denmark

  • Nykøbing Falster Hospital

    Nykøbing Falster, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Randers Hospital

    Randers, Denmark

  • Sjællands Universitetshospital, Roskilde

    Roskilde, Denmark

  • Silkeborg Hospital

    Silkeborg, Denmark

  • Slagelse Sygehus

    Slagelse, Denmark

  • Vejle Hospital

    Vejle, Denmark

  • Viborg Hospital

    Viborg, Denmark

  • Holbæk Hospital

    Holbæk, Region Sjælland, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.